November 19th, 2026sNDA Submitted: Caplyta for the Treatment of Bipolar ManiaJohnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania. Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 16th, 2026FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II DisorderThe FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use. Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more
November 12th, 2026Major Depressive Disorder With Mixed Features: Diagnosis and TreatmentMixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.Read more
November 10th, 2026Lumateperone Shows Significant and Rapid Improvement in Bipolar ManiaIn the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.Read more